A comprehensive comparison of third generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment efficacy and adverse events: A Bayesian meta-analysis
Background: It is a challenge for clinicians to choose the optimal third generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) treatment for individual patients. In this meta-analysis we compare the efficacy of five third-generation EGFR-TKIs, as first-line and second-line therapies for non-small c...
Saved in:
| Main Authors: | Jinyu Yu, PhD, Hanyu Wu, BS, Lu Yang, MD, Wei Liu, PhD, Baoshan Cao, MD, Baosheng Liang, PhD, Yangchun Gu, MD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2025-09-01
|
| Series: | Global Medical Genetics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2699940425000657 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitor
by: Krishna Babu Duggirala, et al.
Published: (2025-07-01) -
Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01) -
Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy
by: Nan Zhao, et al.
Published: (2025-05-01) -
A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer
by: Lu Xia, et al.
Published: (2025-07-01) -
Efficacy of icotinib in advanced lung squamous cell carcinoma
by: Shuai Liang, et al.
Published: (2018-09-01)